NO332441B1 - Sammensetning av Taxotere® og flavopiridol - Google Patents

Sammensetning av Taxotere® og flavopiridol Download PDF

Info

Publication number
NO332441B1
NO332441B1 NO20034124A NO20034124A NO332441B1 NO 332441 B1 NO332441 B1 NO 332441B1 NO 20034124 A NO20034124 A NO 20034124A NO 20034124 A NO20034124 A NO 20034124A NO 332441 B1 NO332441 B1 NO 332441B1
Authority
NO
Norway
Prior art keywords
taxotere
flavopiridol
days
tumor
dose
Prior art date
Application number
NO20034124A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034124D0 (no
NO20034124L (no
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20034124D0 publication Critical patent/NO20034124D0/no
Publication of NO20034124L publication Critical patent/NO20034124L/no
Publication of NO332441B1 publication Critical patent/NO332441B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20034124A 2001-03-23 2003-09-16 Sammensetning av Taxotere® og flavopiridol NO332441B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (3)

Publication Number Publication Date
NO20034124D0 NO20034124D0 (no) 2003-09-16
NO20034124L NO20034124L (no) 2003-09-16
NO332441B1 true NO332441B1 (no) 2012-09-17

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034124A NO332441B1 (no) 2001-03-23 2003-09-16 Sammensetning av Taxotere® og flavopiridol

Country Status (33)

Country Link
US (2) US20020182204A1 (sr)
EP (1) EP1372652B1 (sr)
JP (1) JP2004521140A (sr)
KR (1) KR100879712B1 (sr)
CN (1) CN1498107A (sr)
AR (1) AR034222A1 (sr)
AT (1) ATE395917T1 (sr)
AU (1) AU2002312815B2 (sr)
BR (1) BR0208221A (sr)
CA (1) CA2441441C (sr)
CY (1) CY1110449T1 (sr)
CZ (1) CZ301423B6 (sr)
DE (1) DE60226710D1 (sr)
DK (1) DK1372652T3 (sr)
EA (1) EA007815B1 (sr)
ES (1) ES2305253T3 (sr)
HR (1) HRPK20030766B3 (sr)
HU (1) HU229258B1 (sr)
IL (2) IL158058A0 (sr)
ME (1) MEP16408A (sr)
MX (1) MXPA03007743A (sr)
NO (1) NO332441B1 (sr)
NZ (1) NZ527655A (sr)
PE (1) PE20020907A1 (sr)
PL (1) PL206118B1 (sr)
PT (1) PT1372652E (sr)
RS (1) RS50681B (sr)
SI (1) SI1372652T1 (sr)
SK (1) SK287481B6 (sr)
TW (1) TWI355935B (sr)
UY (1) UY27220A1 (sr)
WO (1) WO2002076484A2 (sr)
ZA (1) ZA200307381B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361746T1 (de) * 2002-03-06 2007-06-15 Medical Res And Education Trus Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
CA2623729A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
RU2013127655A (ru) * 2010-11-19 2014-12-27 Пирамал Энтерпрайзис Лимитед Фармацевтическая комбинация паклитаксела и ингибитора cdk
AU2012235902B2 (en) * 2011-04-01 2015-08-27 Astrazeneca Ab Therapeutic treatment
JP6309454B2 (ja) 2011-11-30 2018-04-11 アストラゼネカ アクチボラグ 癌の併用処置
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
NZ527655A (en) 2006-03-31
HUP0303589A3 (en) 2007-05-02
PE20020907A1 (es) 2002-12-19
DE60226710D1 (de) 2008-07-03
KR20030086318A (ko) 2003-11-07
CN1498107A (zh) 2004-05-19
US20020182204A1 (en) 2002-12-05
PL206118B1 (pl) 2010-07-30
AU2002312815B2 (en) 2006-08-24
UY27220A1 (es) 2002-09-30
AR034222A1 (es) 2004-02-04
NO20034124D0 (no) 2003-09-16
SI1372652T1 (sl) 2008-10-31
JP2004521140A (ja) 2004-07-15
SK11692003A3 (sk) 2004-03-02
HUP0303589A2 (hu) 2004-03-01
CY1110449T1 (el) 2015-04-29
HRP20030766A2 (en) 2005-06-30
US20060128640A1 (en) 2006-06-15
CA2441441A1 (en) 2002-10-03
MXPA03007743A (es) 2004-11-12
CZ20032551A3 (en) 2004-07-14
HU229258B1 (en) 2013-10-28
PL367702A1 (en) 2005-03-07
ZA200307381B (en) 2005-03-30
PT1372652E (pt) 2008-07-24
IL158058A0 (en) 2004-03-28
HRPK20030766B3 (en) 2006-11-30
CZ301423B6 (cs) 2010-02-24
YU69503A (sh) 2006-08-17
NO20034124L (no) 2003-09-16
TWI355935B (en) 2012-01-11
DK1372652T3 (da) 2008-09-22
MEP16408A (en) 2010-10-10
EA200301053A1 (ru) 2004-02-26
SK287481B6 (sk) 2010-11-08
KR100879712B1 (ko) 2009-01-22
ATE395917T1 (de) 2008-06-15
EP1372652B1 (en) 2008-05-21
WO2002076484A2 (en) 2002-10-03
RS50681B (sr) 2010-06-30
IL158058A (en) 2010-02-17
ES2305253T3 (es) 2008-11-01
CA2441441C (en) 2009-05-26
WO2002076484A3 (en) 2003-01-03
EP1372652A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
Finn et al. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Laev et al. Anti-arthritic agents: progress and potential
Fauzee et al. Taxanes: promising anti-cancer drugs
US8173177B2 (en) Compositions of botanical extracts for cancer therapy
US20060128640A1 (en) Combination of a taxane and a cyclin-dependent kinase
Ahmed et al. Calcitriol (1, 25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model
Deep et al. Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review
BRPI0721626A2 (pt) combinaÇço farmacÊutica sinergÍstica para o tratamento de cÂncer
Johnson et al. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
US20030125374A1 (en) Enhancement of taxane-based chemotherapy by a CDK1 antagonist
Shah et al. The relevance of drug sequence in combination chemotherapy
Tang et al. Quercetin exerts synergetic anti-cancer activity with 10-hydroxy camptothecin
Srikumar et al. Potential use of flavopiridol in treatment of chronic diseases
Wang et al. Celastrus orbiculatus extract potentiates the sensitivity of cisplatin via caspase-depenent apoptosis in gastric cancer
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
Suvarna et al. An insight of polyphenols in lung cancer chemoprevention
El Bairi et al. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers
JP2020512408A (ja) 肺がんの治療に使用するための組み合わせ
McGuire Experimental chemotherapy
Zhai et al. Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs. Biomolecules 2021, 11, 1841
CN116531395A (zh) 含青蒿素类衍生物的组合物及在制备治疗白血病药物中的应用
US7985738B2 (en) Cytosine nucleoside analogs and isoflavones and uses thereof
Scheithauer et al. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies
Parchment Cancer treatment

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees